お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
192846

破傷風 : パイプライン製品の分析

Tetanus - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 94 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.75円
破傷風 : パイプライン製品の分析
出版日: 2020年09月30日
発行: Global Markets Direct
ページ情報: 英文 94 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

破傷風とは、破傷風菌により引き起こされる重い疾患です。主な徴候・症状として、あごの筋肉のけいれんや硬直化、嚥下障害、腹筋の硬直化、発熱、発汗、血圧・心拍数の上昇などがあります。疾病素質には火傷や、外科手術による外傷、耳の感染症、外傷部分近辺の浮腫、足部潰瘍(からの感染)などが含まれています。主な治療薬には抗生物質や鎮静剤、β遮断薬などがあります。

当レポートでは、世界各国での破傷風治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

破傷風の概要

治療薬の開発

  • 破傷風向けパイプライン製品:概要
  • 破傷風向けパイプライン製品:比較分析

各企業で開発中の破傷風治療薬

大学/研究機関で研究中の破傷風治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

破傷風治療薬:開発中の製品の一覧(企業別)

破傷風治療薬:研究中の製品の一覧(大学/研究機関別)

破傷風治療薬の開発に従事している企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Bharat Biotech International Limited
  • BioClonetics Immunotherapeutics, Inc.
  • Biological E. Limited
  • Boryung Pharmaceutical Co., Ltd.
  • 第一三共
  • GlaxoSmithKline Plc
  • Green Cross Corporation
  • Indian Immunologicals Limited
  • 化学及血清療法研究所(化血研)
  • LG Life Science LTD.
  • Panacea Biotec Limited
  • Prometheon Pharma, LLC
  • Sanofi Pasteur SA
  • Serum Institute of India Limited
  • Sinovac Biotech Ltd.
  • Zydus Cadila Healthcare Limited

破傷風:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

破傷風治療薬:開発が休止状態の製品

破傷風治療薬:開発が中止された製品

破傷風関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

List of Tables

  • Number of Products under Development for Tetanus, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Tetanus - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2020
  • Tetanus - Pipeline by Beijing Tiantan Biological Products Co Ltd, H2 2020
  • Tetanus - Pipeline by Biken Co Ltd, H2 2020
  • Tetanus - Pipeline by Biological E Ltd, H2 2020
  • Tetanus - Dormant Projects, H2 2020
  • Tetanus - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Tetanus - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Tetanus, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC12565IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tetanus - Pipeline Review, H2 2020, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.

Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury and infected foot ulcers. Treatment includes antibiotics, sedatives and beta blockers.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tetanus - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 9, 7, 9, 1, 9, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Tetanus (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tetanus (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tetanus (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tetanus (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tetanus (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tetanus (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tetanus (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Tetanus - Overview
  • Tetanus - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tetanus - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tetanus - Companies Involved in Therapeutics Development
  • Beijing Minhai Biotechnology Co Ltd
  • Beijing Tiantan Biological Products Co Ltd
  • Biken Co Ltd
  • Biological E Ltd
  • BioNet- Asia Co Ltd
  • Boryung Pharmaceutical Co Ltd
  • Cadila Healthcare Ltd
  • CanSino Biologics Inc
  • Changchun Bcht Biotechnology Co Ltd
  • Chongqing Zhifei Biological Products Co Ltd
  • GC Pharma
  • GlaxoSmithKline Plc
  • KM Biologics Co Ltd
  • LG Chem Ltd
  • Novo Medi Sciences Pvt Ltd
  • NTxBio LLC
  • Olymvax Biopharmaceuticals Inc
  • Panacea Biotec Ltd
  • Sanofi
  • Sanofi Pasteur SA
  • Seasons Healthcare Ltd
  • Serum Institute of India Ltd
  • Shantha Biotechnics Pvt Ltd
  • Sichuan ZehaTimes Pharmaceutical Co Ltd
  • Stablepharma Ltd
  • Yisheng Biopharma Co Ltd
  • Yuxi Jiuzhou Biological Technology Co Ltd
  • Zhuhai Trinomab Biotechnology Co Ltd
  • Tetanus - Drug Profiles
  • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis + tetanus) (pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) (tetravalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenzae [serotype B] + pertussis (whole cell) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tetanus - Dormant Projects
  • Tetanus - Discontinued Products
  • Tetanus - Product Development Milestones
  • Featured News & Press Releases
  • Jan 14, 2019: FDA approves expanded use of Adacel (Tdap) vaccine for repeat vaccination
  • Aug 02, 2016: CanSino submits a clinical trial application for the component DTP diptheria tetanus pertussis combo vaccine (adults, teenagers and children above 6 years Old)
  • Sep 01, 2015: Commercialisation of a world changing invention for the stabilisation and delivery of vaccines
  • Nov 24, 2014: CanSinotech submitted CTA of "Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed" to CFDA
  • Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age
  • Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis
  • Jun 13, 2005: U.S. FDA Licenses sanofi pasteur's ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis
  • Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine
  • Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur's ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis
  • Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults.
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.